Epidemiology, pathophysiology and clinical aspects of Hepatocellular Carcinoma in MAFLD patients
Hepatology International · 2024-10 · 18 (S2) · 922-940
DOI: 10.1007/s12072-024-10692-4 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Hepatology International, online erschienen am 16.07.2024. Verfasst von Maria Eva Argenziano und 6 weiteren Autor:innen. Beteiligte Einrichtung: Clinic of Gastroenterology, Hepatology, and Emergency Digestive Endoscopy, Università Politecnica Delle Marche, 60126,, Ancona, Italy. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms. Die Arbeit wurde bisher 49-mal zitiert (Crossref) und nennt 207 Literaturangaben.
Abstract (Originalsprache)
Hepatocellular carcinoma (HCC) is undergoing a transformative shift, with metabolic-associated fatty liver disease (MAFLD) emerging as a dominant etiology. Diagnostic criteria for MAFLD involve hepatic steatosis and metabolic dysregulation. Globally, MAFLD prevalence stands at 38.77%, significantly linked to the escalating rates of obesity. Epidemiological data indicate a dynamic shift in the major etiologies of hepatocellular carcinoma (HCC), transitioning from viral to metabolic liver diseases. Besides the degree of liver fibrosis, several modifiable lifestyle risk factors, such as type 2 diabetes, obesity, alcohol use, smoking, and HBV, HCV infection contribute to the pathogenesis of HCC. Moreover gut microbiota and genetic variants may contribute to HCC development.The pathophysiological link between MAFLD and HCC involves metabolic dysregulation, impairing glucose and lipid metabolism, inflammation and oxidative stress. Silent presentation poses challenges in early MAFLD-HCC diagnosis. Imaging, biopsy, and AI-assisted techniques aid diagnosis, while HCC surveillance in non-cirrhotic MAFLD patients remains debated.ITA.LI.CA. group proposes a survival-based algorithm for treatment based on Barcelona clinic liver cancer (BCLC) algorithm. Liver resection, transplantation, ablation, and locoregional therapies are applied based on the disease stage. Systemic treatments is promising, with initial immunotherapy results indicating a less favorable response in MAFLD-related HCC.Adopting lifestyle interventions and chemopreventive measures with medications, including aspirin, metformin, and statins, constitute promising approaches for the primary prevention of HCC.Prognosis is influenced by multiple factors, with MAFLD-HCC associated with prolonged survival. Emerging diagnostic biomarkers and epigenomic markers, show promising results for early HCC detection in the MAFLD population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Clinic of Gastroenterology, Hepatology, and Emergency Digestive Endoscopy, Università Politecnica Delle Marche, 60126,, Ancona, Italy.
- Faculty of Medicine and Health Sciences, University of Ghent, Ghent, Belgium.
- Department of Internal Medicine, Yonsei University College of Medicine, 50 Yonsei-Ro, Seodaemun-Gu, Seoul, 03722, Republic of Korea.
- Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Republic of Korea.
- Yonsei Liver Center, Severance Hospital, Seoul, Republic of Korea.
- Department of Internal Medicine, Yonsei University College of Medicine, 50 Yonsei-Ro, Seodaemun-Gu, Seoul, 03722, Republic of Korea. ahnsh@yuhs.ac.
Zitieren
APA
Argenziano, M. E., Kim, M. N., Montori, M., Di Bucchianico, A., Balducci, D., Ahn, S. H., & Svegliati Baroni, G. (2024). Epidemiology, pathophysiology and clinical aspects of Hepatocellular Carcinoma in MAFLD patients. Hepatology International, 18(S2), 922-940. https://doi.org/10.1007/s12072-024-10692-4
Vancouver
Argenziano ME, Kim MN, Montori M, Di Bucchianico A, Balducci D, Ahn SH, et al. Epidemiology, pathophysiology and clinical aspects of Hepatocellular Carcinoma in MAFLD patients. Hepatology International. 2024;18(S2):922-940. doi:10.1007/s12072-024-10692-4
BibTeX
@article{Argenziano2024,
author = {Argenziano, Maria Eva and Kim, Mi Na and Montori, Michele and Di Bucchianico, Alessandro and Balducci, Daniele and Ahn, Sang Hoon and Svegliati Baroni, Gianluca},
title = {Epidemiology, pathophysiology and clinical aspects of Hepatocellular Carcinoma in MAFLD patients},
journal = {Hepatology International},
year = {2024},
volume = {18},
number = {S2},
pages = {922--940},
doi = {10.1007/s12072-024-10692-4}
}
EUVIMED